Pelthos Therapeutics cash flow, quarter by quarter

In Q2 2026, Pelthos Therapeutics generated −$7.7M of operating cash flow and spent $2K on capital projects, leaving free cash flow of −$7.7M. That is $7.2M less than in Q2 2025 (−$447K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$42.3M; the largest uses were operating cash flow ($42.3M), other investing ($5.1M), capital spending ($295K); besides operations, cash came from other financing ($72.2M), net borrowing (+) / repaid (−) ($68K); the cash balance rose by $24.5M.

Operating cash flow was −$7.7M against net income of −$23.4M. The largest differences: accrued liabilities +$8.3M, receivables −$2.8M, stock-based pay +$2.8M.

Its cash conversion cycle was 491 days (receivables 76 + inventory 566 − payables 151).

Pelthos Therapeutics is burning cash: its operations consume cash, a free cash flow of −$42.6M a year at the current rate against $24.2M of cash and investments: a runway of about 7 months before any new financing.